NASDAQ:INMB INmune Bio (INMB) Stock Price, News & Analysis $1.61 +0.01 (+0.63%) Closing price 10/21/2026 04:00 PM EasternExtended Trading$1.60 -0.01 (-0.31%) As of 10/21/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About INmune Bio Stock (NASDAQ:INMB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get INmune Bio alerts:Sign Up Key Stats Today's Range$1.60▼$1.6950-Day Range$1.54▼$2.5152-Week Range$1.09▼$2.60Volume229,970 shsAverage Volume291,480 shsMarket Capitalization$44.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingModerate Buy Company Overview INmune Bio, Inc. is a clinical-stage biotechnology company developing immunotherapies that target the innate immune system. The company’s research focuses on addressing chronic inflammation and improving immune responses in neurological disorders and cancer. Its lead product candidate, XPro, is an investigational selective inhibitor of soluble tumor necrosis factor (TNF), an inflammatory signaling protein. INmune Bio is evaluating XPro in conditions associated with neuroinflammation, including Alzheimer’s disease and depression-related disorders. The company also has an oncology program centered on INKmune, an investigational therapy designed to activate a patient’s natural killer cells against cancer, as well as additional TNF-targeting technologies. INmune Bio was founded in 2015 and is headquartered in Boca Raton, Florida. The company’s programs are being advanced through clinical development and research collaborations, with its work focused primarily on cancer and inflammatory diseases affecting the central nervous system. R.J. Tesi, M.D., is the company’s co-founder and chief executive officer.AI Generated. May Contain Errors. Read More INmune Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreINMB MarketRank™: 0.58831394571 of 5 starsINmune Bio scored higher than 12% of companies evaluated by MarketBeat, and ranked 847th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingModerate Buy Consensus RatingINmune Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageINmune Bio has only been the subject of 1 research reports in the past 90 days.Read more about INmune Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioINmune Bio has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about INmune Bio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.18% of the float of INmune Bio has been sold short.Short Interest Ratio / Days to CoverINmune Bio has a short interest ratio ("days to cover") of 6.96.Change versus previous monthShort interest in INmune Bio has recently increased by 18.06%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldINmune Bio does not currently pay a dividend.Dividend GrowthINmune Bio does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.26 News SentimentINmune Bio has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for INmune Bio this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added INmune Bio to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, INmune Bio insiders have not sold or bought any company stock.Percentage Held by Insiders21.40% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions12.72% of the stock of INmune Bio is held by institutions.Read more about INmune Bio's insider trading history. Receive INMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INMB Stock News HeadlinesINmune Bio Enters Agreement to Distribute Its Ebstrocel TreatmentOctober 21 at 9:11 AM | tipranks.comINmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027October 21 at 7:15 AM | globenewswire.comFederal Reserve’s Disturbing Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider. | Weiss Ratings (Ad)INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with UnipharOctober 21 at 7:00 AM | globenewswire.comQuantum Technology Meets Biotechnology: INmune Bio and Quantum Computing Inc. Team Up to Accelerate Drug DiscoveryOctober 15, 2026 | thestreet.comINmune Bio, Quantum Computing Team Up to Identify New Uses for Alzheimer's DrugOctober 15, 2026 | finance.yahoo.comINmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XProOctober 14, 2026 | insidermonkey.comINmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™October 14, 2026 | prnewswire.comSee More Headlines INMB Stock Analysis - Frequently Asked Questions How have INMB shares performed this year? INmune Bio's stock was trading at $1.56 at the beginning of 2026. Since then, INMB shares have increased by 3.2% and is now trading at $1.61. How were INmune Bio's earnings last quarter? INmune Bio, Inc. (NASDAQ:INMB) announced its earnings results on Thursday, August, 6th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.16. Read the conference call transcript. When did INmune Bio IPO? INmune Bio (INMB) raised $20 million in an IPO on the week of February 4th 2019. The company issued 2,500,000 shares at $8.00 per share. How do I buy shares of INmune Bio? Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of INmune Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that INmune Bio investors own include Cassava Sciences (FLNA), NVIDIA (NVDA), Palantir Technologies (PLTR), Plug Power (PLUG), PayPal (PYPL), Advanced Micro Devices (AMD) and CrowdStrike (CRWD). Company Calendar Last Earnings8/06/2026Today10/21/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 INMB's financial health is in the Green zone, according to TradeSmith. INMB has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:INMB CIK1711754 Webwww.inmunebio.com Phone(858) 964-3720FaxN/AEmployees21Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-82.87% Return on Assets-62.23% Debt Debt-to-Equity RatioN/A Current Ratio4.04 Quick Ratio4.04 Sales & Book Value Annual Sales$50 thousand Price / Sales893.55 Cash FlowN/A Price / Cash FlowN/A Book Value$0.88 per share Price / Book1.83Miscellaneous Outstanding Shares27,750,000Free Float21,815,000Market Cap$44.68 million OptionableOptionable Beta0.89 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:INMB) was last updated on 10/21/2026 by MarketBeat.com Staff. From Our PartnersMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | Sponsored80 Days Until the Pentagon Restricts Chinese Rare EarthsChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
